Acute coronary syndrome (ACS) with elevated ST segment: Consensus strategy for early reperfusion. The public enterprise for health emergencies and the ARIAM project Andalusia;Síndrome coronario agudo con elevación del segmento ST (SCACEST). Estrategia de consenso para una reperfusión precoz. Empresa pública de emergencias sanitarias (EPES) y grupo ARIAM-Andalucía

Medicina Intensiva

Volumn 31, Issue 9, 2007, Pages 502-509

  Rosell Ortiz, F ^a,h   Mellado Vergel, F J ^b   Ruiz Bailen M ^c   Garcia Alcantara A ^d   Reina Toral, A ^e   Arias Garrido, J ^f   Alvarez Bueno M ^g  

^a Empresa Pública de Emergencias Sanitarias de Andalucía   (Spain)

^b Hospital de Alta Resolución El Toyo   (Spain)

^c Servicio de Cuidados Críticos   (Spain)

^d Hospital Clinico de Malaga   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^f HOSPITAL DE JEREZ   (Spain)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h Servicio 061   (Spain)

Author keywords

Acute ST elevation myocardial infarction; Fibrinolysis; Percutaneous coronary intervention; Reperfusion treatment

Indexed keywords

ACUTE CORONARY SYNDROME; ARTICLE; CARDIAC PATIENT; CLINICAL DECISION MAKING; CONTROLLED STUDY; DEFIBRILLATION; EMERGENCY CARE; HUMAN; MEDICAL PRACTICE; PATIENT CARE; REPERFUSION; ST SEGMENT ELEVATION;

EID: 36849052276     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/S0210-5691(07)74857-X     Document Type: Article

References (29)

1. Van de Werf Chair F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003:24;28-66.
2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004. Disponible en: www.acc.org/clinical/guidelines/stemi/index.pdf.
3. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction. Lancet. 1996;348:771-5.
4. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Circulation. 2004;109:1223-5.
5. Silber S, Albertsson P, Avilés FF, Camiri PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions. Eur Heart J. Doi: 10.1093/eurheartj/ehi138. Disponible en: http://www.escardio.org/NR/rdonlyres/8A67A7F4-B954-4137-9E82- BA867FAB1320/0/PCIehi138aheadofpringMarch152005.pdf
6. Giugliano RP, Braunwald E. Selecting the best reperfusion strategy in ST-elevation myocardial infarction. It's all a matter of time. Circulation. 2003;108:2828-30.
7. Gersh BJ, Gregg W. Stone GW, Harvey D, White HD, Holmes DR. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction. Is the slope of the curve the shape of the future? JAMA. 2005;293:979-86.
8. Williams DO. Treatment delayed is treatment denied. Circulation. 2004;109:1806-8.
9. KAA FG, Goodman GW, Klein WD, Brieger DPG, Steg PG, Dabbous O. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the global registry of acute coronary events (GRACE). Eur Heart J. 2002;23:1177-89.
10. Hasdai D, Behar SL, Wallentin L, Danchin NAK, Gitt AK, Boersma E, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. Eur Heart J. 2002;23:1190-201.
11. Gibson M. NRMI and current treatment patterns for STelevation myocardial infarction. Am Heart J. 2004;148:S29-33.
12. Plan Integral de Atención a las Cardiopatías de Andalucía, 2005-2009. Consejería de Salud de la Junta de Andalucía. Sevilla; 2005. Disponible en: http://www.csalud.junta- andalucia. es
13. Ministerio de Sanidad y Consumo. Plan Integral de Cardiopatía Isquémica 2004-2007. Secretaría General de Sanidad. Ministerio de Sanidad y Consumo. Madrid: Centro de Publicaciones; 2003.
14. Mellado Vergel FJ, Rosell Ortiz F, Ruiz Bailén M, en nombre del grupo PEFEX. Tratamiento extrahospitalario del infarto agudo de miocardio en Andalucía. Rev Esp Cardiol. 2005; 58:1287-93.
15. Rosell F, Mellado FJ, Ruiz-Bailén M, Paz-Rodríguez MA, Martínez-Faure J, Vivar I, et al on behalf of PEFEX investigators. Pre-hospital treatment improves 1-year survival of patients with acute myocardial infarction with ST segment elevation. (ABSTRACT). Circulation. 2006;114:119.
16. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-89.
17. Sabatine MS, Morrow DA, Montalescot G, Dellborg M, Leiva-Pons JL, Keltai M, et al. Clopidogrel as adjunctive reperfusion therapy (CLARITY)-thrombolysis in myocardial infarction (TIMI) 28 Investigators. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation. 2005;112:3846-54.
18. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622-32.
19. Wallentin L, Goldstein P, Armstrong P W, Granger CB, Adgey AAJ, Arntz H R, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting. The assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003;108:135-42.
20. Antman E, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al for the ExTRACT-TIMI 25 Investigators Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial Infarction. N Engl J Med. 2006;354:1477-88.
21. Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, et al; SYNERGY Trial Investigators. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA. 2005;294:2594-600.
22. Grines C. SENIOR PAMI. A prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial infarction. Washington, DC: TCT 2005. October 16-21.
23. Kastrati A, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, et al; Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA. 2004;291:947-54.
24. Stone GW, Grines CL, Cox DA, García E, Tcheng JE, Griffin JJ, et al; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-66.
25. Fernández-Avilés F, Alonso JJ, Castro-Beiras A, Vázquez N, Blanco J, Alonso-Briales J, et al; GRACIA (Grupo de análisis de la cardiopatía isquémica aguda) Group. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with STsegment elevation (GRACIA-1): a randomised controlled trial. Lancet. 2004;364:1045-53.
26. Ellis S, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, et al, on behalf of the FINESSE Investigators. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J. 2004;147:e16.
27. Fernández-Avilés F, Alonso JJ, Pena G, Blanco J, Alonso-Briales J, López-Mesa J. Primary angioplasty vs early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart. 2007;28:949-60.
28. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569-78.
29. Armstrong PW, for the WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J. 2006;27:1530-8.